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Abstract: The prevalence of gastroesophageal reﬂ  ux disease (GERD) increases with age and 
elderly are more likely to develop severe disease. Older patients often complain of less severe 
or frequent heartburn than younger patients and they may present with atypical symptoms such 
as dysphagia, weight loss, or extraesophageal symptoms. Proton pump inhibitors (PPIs) are 
central in the management of GERD and are unchallenged with regards to their efﬁ  cacy. They 
are considered safe and more effective than histamine receptor antagonists for healing esophagitis 
and for preventing its recurrence using a long term maintenance treatment. PPI have minimal 
side effects and few slight drug interactions and are considered safe for long term treatment. 
Pantoprazole is signiﬁ  cantly effective both for acute and long-term treatment with excellent 
control of relapse and symptoms. It is well tolerated even for long-term therapy and its tolerability 
is optimal. Pantoprazole shows to have minimal interactions with other drugs because of a lower 
afﬁ  nity for cytocrome P450 than older PPIs. Although the majority of elderly has concomitant 
illnesses and receive other drugs, this does not adversely effect the efﬁ  cacy of pantoprazole 
because of its pharmacokinetics, which are independent of patient age. Clinical practice suggests 
that a low dose maintenance of PPIs should be used in older patients with GERD.
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Introduction
The reﬂ  ux of gastric contents from the stomach into esophagus is well recognized to 
play a major role in the pathogenesis of gastroesophageal reﬂ  ux disease (GERD).
Signiﬁ  cant information has accumulated over the past decade to support the position 
that the proton pump inhibitors (PPIs) represent powerful drugs that are especially 
effective in the treatment of GERD. These drugs inhibit the ﬁ  nal common pathway 
to acid secretion, the H+/K+ ATPase located in the secretory canalicular membrane 
of the gastric parietal cell (Sachs et al 1993). In addition a long acting inhibition of 
gastric acid secretion occurs because of the covalent bonds formed by PPIs with the 
H+/K+ ATPase (Shin and Sachs 2002). As a consequence of their ability to signiﬁ  cantly 
suppress acid secretion, PPIs are the preferred class of therapeutic agents for the 
treatment of GERD.
Symptom relief and acute healing of esophageal lesions can be achieved with 
short-term treatment. It has been demonstrated that healing regards not only erosive 
esophagitis but also negative endoscopy esophagitis (NERD) at the ultrastructural 
view of the mucosa (Calabrese, Bortolotti, et al 2005).
Otherwise, GERD is a chronic relapsing disease requiring long-term therapy in 
most patients. The high prevalence of chronic discomfort, which may or may not 
be associated with macroscopic esophagitis or related complications, decreases the 
patient’s quality of life, increases the need for physician of visits and hospitalizations, 
and is costly for society. Most GERD patients require long term treatment to remain Clinical Interventions in Aging 2007:2(1) 86
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asymptomatic and/or sustain esophageal healing (Earnest 
and Robinson 1999; Katz 1999). The proportion of patients 
remaining in remission is very low at only 10%–25%, after 
six months of therapy (Dent et al 1999). Patients with NERD 
experience relapse over 6 months, and in more severe cases 
of erosive esophagitis (particularly Los Angeles classiﬁ  cation 
grades C and D), relapse rate has been calculated between 
80%–90% (Ollyo et al 1993; Lieberman 1987; Venables 
et al 1997b; Hetzel et al 1998; Sandmark et al 1998; Richter 
et al 2004). Due to this marked tendency towards relapse, 
almost all patients with GERD, regardless of endoscopic 
status, need an effective long-term management strategy 
for adequate symptom control, maintenance of mucosal 
healing, prevention of complications, and improvement of 
quality of life. Particularly, a maintenance therapy on a daily 
basis has been advocated in patients with severe esophagitis. 
Reports indicate that long-term therapy with appropriate PPI 
maintenance doses can be effective in as many as 100% of 
GERD patients (Katz 1999).
Recently acid-suppressive therapy ‘on demand’ has 
been proposed as an alternative to maintenance therapy; the 
patients decide when to start and to stop treatment. In this 
way the therapeutic strategy is likely to be more cost-effective 
than day by day maintenance therapy. Otherwise, the few 
data published to date regards only patients with grades A–B 
esophagitis (Bardan et al 1999; Kaspari et al 2005; Scholten 
et al 2005). Johnsson and colleagues (2002) suggested that 
it is the patient’s habits more than symptoms that determine 
the frequency and interval of medication intake since the 
patient could not ﬁ  nd any correlation between the severity 
of the disease and medication intake. Several studies, and in 
particular, Venables and colleagues (1997a) who evaluated 
nearly 1000 patients (32% with erosive esophagitis), 
report that neither the physician evaluation nor a validated 
questionnaire that segregated patients into mild, moderate, 
or severe symptoms were predictive of erosive esophagitis 
(Venables et al 1997a; Devault 2006). ‘On demand therapy’ 
can be inadequate if the severity of the disease is not well 
documented because of the unpredictability of its course.
There is no consensus or agreed deﬁ  nition on what 
constitutes long term PPIs prescription. The deﬁ  nition has 
varied: from one repeated prescription over 12 months to 
continuous therapy for periods ranging from 4 to >12 months  
(Table 1) (Ryder et al 1994; Roberts and Bateman 1995; 
Rubin et al 1995; Goudie et al 1996; Ahnfeldt-Mollerup et al 
1997; Boutet et al 1999; Hungin et al 1999; Prach et al 1999; 
Vetvik and Straand 2001; Hurenkamp et al 2002; Chen et al 
2003; Jacobson et al 2003; Majumdar et al 2003; Lassen 
et al 2004; Raghunath and Hungin 2004; Tsai et al 2004; 
Raghunath et al 2005).
GERD is a very common complaint when considering the 
management of treatment with PPIs in the population over 
65 years of age. GERD is usually more severe in the elderly 
than in younger patients and is frequently under-diagnosed 
and under-treated. Although there are a number of published 
articles reviewing the relative merits and limitations of the 
various therapy options for relapsing GERD, relatively 
few of them have speciﬁ  cally considered the elderly. In 
particular, there has been concern about the effects of 
different PPIs when coadministered with other drugs, such as 
benzodiazepin, warfarin, and digoxin, which are frequently 
used by older subjects.
Efﬁ  cacy, safety, and tolerability 
of pantoprazole
Pantoprazole is a PPI that has been evaluated in more than 
100 clinical trials (van Zyl et al 2004). It is a substituted 
benzimidazole derivative. Pantoprazole has a higher chemical 
stability at neutral and moderately acidic pH compared with 
other PPIs, which makes it less likely to become activated 
in moderately acidic compartments of the body. Most 
importantly, it has a low potential for metabolic interactions 
with cytochrome P450-dependent oxidase system and so it is 
particularly suitable for patients in co-medications (Stupnicki 
et al 2004).
Orally administered pantoprazole is very effective in 
GERD and achieves high healing rates as well as successful 
relief of symptoms (van Zyl et al 2004). Bardhan and 
colleagues (2005) reported that most patients need only the 
standard dose of 40 mg and healing occurs within 4 weeks 
in the vast majority. Otherwise, a maintenance treatment 
is advocated because of the high incidence of relapse of 
esophagitis. Prolonged pantoprazole therapy, also lasting up 
to 5 years, is also effective for the long term management 
of severe ulcers and reﬂ  ux disease (Bardhan et al 2005). 
A particular concern regards GERD and its association 
with extra-esophageal complications and in particular with 
intrinsic asthma. In this case a high-dose long-term PPI 
treatment has been advocated. A recent study (Calabrese, 
Fabbri, et al 2005) showed that mild persistent asthma, 
besides having a highly prevalent relation with GERD, 
improves till a complete regression with 80 mg/daily for 
6 months of pantoprazole. Twelve months follow up was 
carried out in this work. A possible occurring of a relapse Clinical Interventions in Aging 2007:2(1) 87
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of GERD and asthma after discontinuation of treatment is 
not known.
PPIs, and among them pantoprazole, produce superior 
symptomatic remission rates and clinical efﬁ  cacy compared 
with H2 antagonist (such as ranitidine). Moreover 
pharmacokinetic considerations suggest that H2 antagonist 
present a progressive phenomena of tolerance with continuous 
administration, leading to a consequent shortening of the 
clinical efﬁ  cacy (Jalving et al 2006). For example, in a study 
of comparison with ranitidine, (Richter et al 2004) reports 
that pantoprazole provided the greatest degree and the most 
consistent effect for all efﬁ  cacy parameters compared with 
the ranitidine throughout the 12 months of evaluation (van 
Zyl et al 2004).
Maintenance dosage is not well established. Patients with 
moderate to severe symptoms of esophagitis, whose disease 
has been initially controlled with PPIs, frequently, require 
PPI maintenance dosages similar to those used for initial 
esophageal healing (Donnellan et al 2005; Berardi 2006). 
A dissimilar result was found in a recent European trial 
(Escourrou et al 1999), which indicated that pantoprazole 
20 mg/day was at least as effective as 40 mg/day with 
respect to prevent symptomatic and endoscopic recurrence 
in patients with grade B and C esophagitis who were 
initially healed with either pantoprazole (40 mg/day) or 
omeprazole (20 mg/day).
Data on the safety of prolonged therapy with PPI and 
pantoprazole are relatively sparse. In early days there was 
particular concern about hypergastrinemia in response 
to profound acid inhibition with resultant endocrine cell 
hyperplasia and possible tumor formation. Endocrine cell 
hyperplasia has been looked for in Man but is rarely found 
in the few reported studies. The development of frank 
carcinoid tumors is described to be exceptional (Laine 
et al 2000; Bardhan et al 2005; Jalving et al 2006). There is 
inadequate evidence to support the association between 
PPIs and colonic polyps and no data has been reported on 
pantoprazole and an association with gastric or colorectal 
neoplasia in humans (Berardi 2006). Other concerns are 
about the possible bacterial overgrowth with consequent 
nitrosamine formation induced by the suppression of gastric 
acid in patients treated with PPIs. Helicobactor pylori and 
many other urease positive gastric bacteria can be advocated 
at this point (Brandi et al 2006). A causal relationship between 
intragastric nitrosamine and gastric development of neoplasia in 
patients taking PPIs has never been established (Freston 1997; 
Garnett 1998). The inﬂ  uence of H. pylori infection during 
prolonged PPIs therapy is still in doubt. Reductions in chronic 
antral gastritis and corresponding increases in chronic corpus 
gastritis in those with H. pylori infection have been observed; 
in contrast, there is little change in the uninfected. A corpus 
gland atrophy has been also observed and it develops in some 
Table 1 Rates of long-term PPIs use
References Country  Deﬁ  nition  Population size
Ryder et al 1994  UK  Six months or more  60 148
Chen et al 2003
Roberts and Bateman 1995  UK  All PPI prescribing in a deﬁ  ned period  41 GP practices
Rubin et al 1995  UK  >12 months  24 400
Goudie et al 1996  UK  Repeat prescribing register  15 495
Boutet et al 1999  Sicily, UK  Repeat prescribing register  42 GP practices
Hungin et al 1999  UK  6 months or more  46 650
Prach et al 1999  UK  More than 56 days/year  35 000
Roberts and Bateman 1995
Vetvick and Straand 2001  Norway  ddu  17 105
Jacobson et al 2003
Ahnfeldt-Mollerup et al 1997  Denmark  Constant treatment  7160
Hurenkamp et al 2002  Holland  More than 12 weeks  46 813
Tsai et al 2004
Chen et al 2003  Taiwan  Prescription items and ddu  /
Jacobson et al 2003  USA  More than 90 days  168 727
Raghunath and Hungin 2004  UK  Six months or more  46 933
Lassen et al 2004  Denmark  >180 ddu/year  470 000
Majumdar et al 2003  USA  Equal to or more one year  216 720
Abbreviations: ddu, daily deﬁ  ned units; GP, general practitioner; PPIs, proton pump inhibitors. Clinical Interventions in Aging 2007:2(1) 88
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H. pylori-infected patients. This observation could raise 
a theoretical risk of tumor development, but other studies 
have not been able to conﬁ  rm this progression. Hence, there 
is no agreement on whether to eradicate H. pylori before 
commencing long-term PPIs therapy (Bardhan et al 2005).
Digestion of protein and the absorption of calcium and 
iron are normal in patients treated with PPIs (Garnett 1998). 
Only a slight decrease of B12 serum concentration has been 
reported in a small number of patients on long term therapy 
(longer than 3 years) but only with omeprazole and this 
appeared to not be a major clinical concern (Garnett 1998).
Less is known about safety of pantoprazole during 
pregnancy. Data reported are only for omeprazole and they 
suggest that, until it is possible to rule out an association 
between PPIs and an increased risk of fetal malformations 
or preterm birth, the beneﬁ  t of using a PPI during pregnancy 
must be weighted against the potential risk for the fetus 
(Berardi 2006).
Pantoprazole is overall a well tolerated drug. Most 
recurrent short-term adverse effects are headache, diarrhea, 
nausea, and abdominal pain. These events are uncommon 
(approximately 1%) and rarely lead to withdrawal of 
treatment. Data from numerous clinical trials and clinical 
experience conﬁ  rm the short-term adverse effects of PPIs 
and also of pantoprazole (Fitton and Wiseman 1996; Dupas 
et al 1998; Richardson et al 1998; Vicari et al 1998).
Data from long-term studies with pantoprazole suggest a 
similar tolerability to that reported with their short-term use 
(Fitton and Wiseman 1996; Moosner et al 1997; Richardson 
et al 1998; Escourrou et al 1999).
Quality of life, patient’s satisfaction/
acceptability, adherence, 
and reuptake
Since impairment of normal life consequent upon GERD 
symptoms (health-related quality of life [HRQoL]) is 
generally the primary motive of the patient to seek therapy, 
the relief of typical GERD symptoms is of considerable 
interest for patients. From the perspective of the patient, 
symptom relief is the most critical component in determining 
the success of treatment. Numerous previous data clearly 
indicate that the frequency and severity of common 
GERD-related symptoms correlate with an impairment of 
normal functioning and general well-being (Dupas et al 
1998; Kaplan-Machlis et al 1999). An adequate control of 
symptoms and a sustained reduction of symptoms to a level 
that does not signiﬁ  cantly impair HRQoL is the end-point 
of treatment (Dimenas et al 1996). The speed of the change 
in HRQoL during therapy may inﬂ  uence the choice of the 
treatment drug.
Tools to assess how symptoms of GERD relate to and 
impair HRQoL are important for a better understanding of 
diagnosis and treatment.
In contrast to the obsolete assessment of heartburn as 
a single outcome criterion, a recently validated symptom 
assessment scale (ReQuest) (Monnikes et al 2005) reliably 
covers a broad range of GERD-related symptoms on a daily 
basis by its dimension-orientated structure. An evaluation 
study using ReQuest demonstrated that even individuals 
without evidence of GERD experienced mild symptoms that 
are commonly related to GERD.
In the study by Monnikes and colleagues (2005), the 
rapid and sustained relief of a wide range of symptoms 
is documented in patients with NERD treated with 20 mg 
pantoprazole. The median time to ﬁ  rst symptom relief was 
2 days. This study is in accordance with the literature that 
treatment can achieve effect in a matter of days (Dent et al 
1999; Kovacs et al 2002; Moretzsohn et al 2002). Moreover, 
the data indicates that pantoprazole is well tolerated, safe and 
provide efﬁ  cacy in time to both ﬁ  rst and sustained symptom 
relief in patients with NERD. Pantoprazole is strictly related 
to a rapid and sustained relief with the minor short term 
adverse effects with regards to patient satisfaction and 
acceptability. PPIs and pantoprazole reﬂ  ect this end-point. 
Adherence and uptake is another point of interest. 
Compliance with continuous PPIs therapy is poor: only a 
minority of patients regularly requests their prescriptions. 
The main factors determining whether or not patients take 
their PPI is the presence or severity of symptoms, the desire 
to remain in personal control, ignorance about the drugs, and 
a fear of side effects (Hungin et al 1999) despite PPIs being 
a well tolerated class of drugs.
Special considerations in the elderly
The goals of treatment of GERD in the elderly are essentially 
the same as those for other age groups: to alleviate symp-
toms; to heal esophagitis; to manage complications; and to 
maintain remission.
GERD is a widespread problem in the elderly, but the 
incidence of GERD in older patients is difﬁ  cult to deﬁ  ne 
because of the limited number of studies addressing 
the population age >65 years. In addition, co-morbidity 
with increasing age and the use of concomitant therapies 
complicate both diagnosis and management. In the primary Clinical Interventions in Aging 2007:2(1) 89
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care setting in the US, as many as 20% of older patients 
report acid reﬂ  ux (Mold et al 1991). In a Japanese study, the 
prevalence of reﬂ  ux esophagitis in patients aged >70 years 
was more than triple the prevalence in patients younger than 
39 years (Maekava et al 1998). 
Interestingly, there are signiﬁ  cant differences between 
elderly and younger patients in the presentation of GERD. 
Older subjects with GERD are less likely to report frequent 
or severe heartburn and the majority do not experience acid 
regurgitation (Raiha et al 1991). Dysphagia usually occurs in 
the setting of long standing heartburn with slow progressive 
dysphagia for solid and rarely for liquids. Weight loss is 
infrequent because appetite is unchanged, which helps 
distinguish this usually benign dysphagia. This symptom 
is usually correlated to a peptic stricture, severe peristaltic 
dysfunction, and sometimes the ﬁ  rst presentation of Barrett’s 
esophagus with cancer (Raiha et al 1992). Extraesophageal 
presentation of GERD are more common in the elderly 
(Raiha et al 1992). The chest pain produced by acid reﬂ  ux 
may be identical in quality to angina, making an appropriate 
diagnosis a difﬁ  cult problem. Because of this different 
symptom profile of GERD in the elderly, the disease, 
particularly in the milder form, may remain undiagnosed 
and untreated for a long period of time.
The management of GERD in the older patient poses 
special challenges. GERD among older people shows a higher 
incidence of severe esophagitis and of its complications, ie, 
bleeding, stenosis, and Barrett’s esophagus. The disease 
presentation is more severe despite milder symptoms because 
of the cumulative injury of acid reﬂ  ux over many years. A 
large epidemiological study from the US reported that age 
was an important risk factor for the development of severe 
forms of GERD, together with male gender, white ethnicity, 
and hiatus hernia (el-Serag and Sonnenberg 1997). Collen 
and colleagues (1995) noted that 81% of GERD patients aged 
60 years or older developed erosive esophagitis compared 
with 47% of those younger than 60 years with GERD.
Some other factors related to the development of GERD 
in the older patient are: a greater degree of nocturnal and 
supine reﬂ  ux; the increased prevalence of hiatus hernia; 
reduced patient mobility and increased recumbence; altered 
gastrointestinal mobility; decreased saliva volume and 
bicarbonate secretion; and increased prevalence of co-morbid 
conditions affecting esophageal tone (ie, diabetes, cerebro-
vascular accident, Parkinson’s disease, and increased 
usage of concomitant medication) (Mold et al 1991; Hungin 
et al 1999).
The management of long-term treatment is a major point 
of interest because of the high occurrence of relapse after 
cessation of therapy. In fact, symptoms and esophagitis 
recur quickly if therapy is not continuative and long-term 
treatment appears to be the key to effective management. 
The intermittent use of antacids, alginic acid, or H2 receptor 
antagonists are usually helpful in relieving mild symptoms, 
if present, but do not heal esophagitis. Continuous PPI 
therapy is particularly useful in elderly patients with GERD 
to obtain a profound acid inhibition and to maintain complete 
symptom relief and healing of esophagitis. A placebo-
controlled clinical trial demonstrates that maintenance 
therapy with pantoprazole 20 mg daily is an effective measure 
for minimizing the occurrence of relapse in patients over 
65 years of age (Maekava et al 1998). In the maintenance 
period of the study, 80% of patients treated with placebo had 
an esophagitis relapse compared with 30% of patients who 
continued active treatment. Moreover, the study reports an 
intention-to-treat healing of 80% after 12 months of treatment 
with 20 mg of pantoprazole, which conﬁ  rms that this low 
dosage is sufﬁ  cient to reduce relapse. Interestingly, 76% 
of patients were affected by concomitant diseases and 65% 
were taking other drugs concomitantly with pantoprazole in 
this population. The low adverse reactions and relapse rates 
conﬁ  rmed that pantoprazole interacted minimally with other 
drugs and suggested that it could be used successfully in 
patients with multiple therapies.
Another study indicates that esophagitis relapse rates in 
elderly who were not treated with maintenance therapy were 
constant during three years of follow up (relapse rates of 
65.5%, 63.6%, and 57.1% after 1, 2, and 3 years respectively) 
(el-Serag and Sonnenburg 1997).
A recent study focused on the managing of GERD in the 
elderly and posed the question about the better dosage to 
prevent relapse of heartburn compared with placebo (Hungin 
et al 1999). The study suggests that the most effective therapy 
is a full dose PPI than a low dose (average relapse rate with 
low dose was 28% and 13% with full dose). Instead, a study 
by Escourrou and colleagues (1999) suggests a maintenance 
therapy with pantoprazole 20 mg daily for six months to 
prevent relapse of reﬂ  ux esophagitis and shows that it is at 
least equivalent to the 40 mg dose. It is without doubt that 
besides the necessity of a long-term treatment in the elderly 
with GERD, there is no general consensus on the optimal 
dosage.
An important problem is the interaction of PPIs with 
other drugs. It is known that the interaction occurs through Clinical Interventions in Aging 2007:2(1) 90
Calabrese et al
the cytochrome P450 systems potentiating other drugs. The 
drugs most cited are benzodiazepines, theophylline, and the 
calcium-channel blockers, but their effects seem to be slight 
(Raiha et al 1991) (Table 2). The most signiﬁ  cant interaction 
is suggested to be between PPIs and warfarin. Also in this 
case it has been shown that 16% of patients on warfarin, 
taking an acid suppressive drug, presented ﬂ  uctuations in 
international normalized ratio (INR) but only in those in 
intermittent PPIs (Raiha et al 1992). Pantoprazole has shown 
to have fewer drug interactions than older PPIs because of 
a lower afﬁ  nity for cytocrome P450 (Stupnicki et al 2004). 
Moreover a pharmacokinetics evaluation of pantoprazole 
shows that it may be a good choice for the treatment of the 
older patient with GERD because it is also independent of 
the patient’s age (Pilotto et al 2005).
Dosage adjustments for PPIs are not necessary in 
elderly patients experiencing renal failure and mild hepatic 
impairment. Pantoprazole should be used with caution in 
patients with severe hepatic impairment (Raiha et al 2005). 
There is concern regarding the use of nonsteroidal anti-
inﬂ  ammatory drugs (NSAIDs) that elderly widely use to 
provide effective pain relief in chronic arthritic, inﬂ  ammatory 
conditions, and prophylaxis against cardiovascular events. 
However, despite the great beneﬁ  ts associated with NSAIDs 
use, up to 25% of patients taking NSAIDs experience 
chronic upper gastrointestinal adverse effects (Singh and 
Triadaphilopoulos 1999). Among adverse effects, severe 
complications of the gastro-intestinal tract are included, and 
it has been estimated a 4% of major accidents in the older 
subject (Armstrong and Blower 1997).
PPIs such as pantoprazole are emerging as effective 
agents that protect the stomach and the duodenum during 
NSAID administration (Cheer et al 2003).
A study in healthy volunteers has shown that even a 
low dose of aspirin causes signiﬁ  cant injury to the stomach 
whereas coadministration with pantoprazole offers protection 
against such damage (Muller and Simon 1998). This 
gastroprotective effect of pantoprazole translates into clinical 
beneﬁ  ts by reducing the damage in long-term users.
Pantoprazole has also been shown to be superior to 
placebo in the prevention of NSAIDs-associated peptic 
ulcers (Bianchi Porro et al 2000). In this study pantoprazole 
40 mg once daily or placebo was administered for 12 weeks 
to patients requiring long-term NSAIDs. At baseline about 
half of patients had endoscopically detected gastroduodenal 
lesions while the other half had normal or hyperaemic mucosa 
at baseline. After 12 weeks the probability of remaining free 
of gastric or duodenal ulcers was 72% in the pantoprazole 
group compared with 59% in the placebo group.
An other study focused on the prevention of NSAIDs-
associated lesions and it concluded that for patients taking 
NSAIDs continually, pantoprazole 20 mg once daily or 
omeprazole 20 mg once daily provided effective and well-
tolerated prophylaxis against gastrointestinal lesions (Regula 
and Butruk 2006). Regarding the use of misoprostol in the 
prevention of gastrointestinal lesions, a interesting study 
shows that pantoprazole 20 mg once daily is superior to 
misoprostol 200 μg twice daily in the prevention of lesions 
and symptoms in patients on continuous long-term treatment 
with NSAID and at risk to develop such lesions or symptoms 
(Stupnicki et al 2003).
Conclusions
This review shows that PPIs are highly effective drugs that have 
revolutionized the management of GERD. Pantoprazole is sig-
niﬁ  cantly efﬁ  cacious both for acute esophageal healing both 
for long-term treatment with excellent control of relapse of 
esophagitis and symptoms. This report also conﬁ  rms that panto-
prazole is a well tolerated treatment even for long-term therapy 
with optimal tolerability. It is perfectly suited for use in patients 
taking concomitant therapies and in particular in the elderly.
There is a limited body of evidence advocating the 
optimal dosage for long-term treatment. Clinical practice 
suggests that at least a low dose maintenance should be 
carefully taken in consideration especially in the elderly as 
they are more exposed to severe complications.
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